NCT05582941|Completed
Biomarkers of Cognitive Impairment in Blood Cells
COGNIMARK
Use of Human Blood Cells for the Identification of Early Biomarkers of Cognitive Damage
Loading search results
COGNIMARK
Use of Human Blood Cells for the Identification of Early Biomarkers of Cognitive Damage
Sponsor study identifier
observational
48
1 country
1
Study Start
April 1, 2022
Actual (reported)Primary Completion
May 31, 2023
Actual (reported)Study Completion
May 31, 2023
Actual (reported)The aim of this study is to identify transcriptomic biomarkers in blood cells to diagnose early cognitive impairment. This would allow preventing the development of severe pathologies, such as Alzheimer Disease. In addition, this project will analyse the influence of adiposity, obesity, nutritional habits and physical activity on cognition.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 31, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 1, 2022
Actual (reported)July 28, 2022
Actual (reported)October 17, 2022
Actual (reported)May 31, 2023
Actual (reported)May 31, 2023
Actual (reported)Percentage of semiquantitative gene expression of blood cells between the three groups
Gene expression analysis performed by real-time quantitative polymerase chain reaction (RT-qPCR). Percentage of semiquantitative gene expression between the groups: MCI vs Control, AD vs Control, and MCI vs AD
Baseline point (all groups)
Mini-Mental State Examination (MMSE), questionnaire (numerical scale)
Cognitive test
Baseline point (all groups)
Montreal Cognitive Assessment (MoCA), questionnaire (numerical scale)
Cognitive test
Baseline point (all groups)
Cognitive Reserve Questionnaire (CRIq), questionnaire (numerical scale)
Cognitive test
Baseline point (all groups)
Height (cm)
Baseline point (all groups)
Weight (kg)
Baseline point (all groups)
Waist-hip ratio (numerical ratio)
Baseline point (all groups)
Blood pressure (mm Hg)
Baseline point (all groups)
Body Mass Index (BMI) (kg/m2)
Baseline point (all groups)
20 individuals with no cognitive alterations or any other pathology which could alter cognitive performance or blood cells
20 individuals diagnosed with Mild Cognitive Impairment Due to Alzheimer's Disease with positive AD markers in cerebrospinal fluid
20 individuals diagnosed with Dementia Due to Alzheimer Disease with positive AD markers in cerebrospinal fluid
No intervention will be performed.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
All of the participants are from Spain. * Control group: the majority are recruited from an Adult University (UOM, Universitat Oberta per Majors, University of the Balearic Island). * Mild Cognitive Impairment and Alzheimer Disease groups: are recruited from the University Hospital, Son Espases, Mallorca, Spain.
University of the Balearic Islands
Palma, Mallorca, Balearic Islands, 07122, Spain
Blood samples for analysis of gene expression and general clinical parameters
Paula Oliver, Professor
University of the Balearic Islands
48 participants (actual enrollment reported by the registry).
First Submitted
July 28, 2022
First Posted
October 17, 2022
Study Start
April 1, 2022
Actual (reported)AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
Body composition (fat mass)
Percentage of fat mass measured using a dual energy x-ray absorptiometry (DXA) scanner
Baseline point (all groups)
Contact the study team to confirm eligibility.
Primary Completion
May 31, 2023
Actual (reported)Study Completion
May 31, 2023
Actual (reported)Last Updated
July 4, 2025
Record last verified: 2023-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: